Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 7/20 | 0.57 |
| ▸ | CASP1 | P29466 | 4/20 | 0.57 |
| ▸ | CASP9 | P55211 | 4/20 | 0.57 |
| ▸ | CASP4 | P49662 | 2/20 | 0.57 |
| ▸ | CASP5 | P51878 | 2/20 | 0.57 |
| ▸ | CASP6 | P55212 | 2/20 | 0.57 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.57 |
| ▸ | CASP10 | Q92851 | 2/20 | 0.57 |
| ▸ | CASP7 | P55210 | 3/20 | 0.55 |
| ▸ | CTSB | P07858 | 5/20 | 0.49 |
| ▸ | CTSL | P07711 | 3/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 4/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2038060 | 0.95 | CASP3 (0.63) | CASP3CASP1CASP9CASP4CASP5 | |
| SCHEMBL23613622 | 0.93 | CASP3 (0.56) | CASP3CASP1CASP9CASP4CASP5 | |
| SCHEMBL30541131 | 0.91 | CASP3 (0.61) | CASP3CASP1CASP9CASP4CASP5 | |
| SCHEMBL7168373 | 0.89 | CASP1 (0.58) | CASP3CASP1CASP9CASP7CTSB | |
| SCHEMBL2038936 | 0.88 | CASP3 (0.69) | CASP3CASP1CASP9CASP4CASP5 | |
| SCHEMBL31248472 | 0.86 | CASP3 (0.63) | CASP3CASP1CASP9CASP4CASP5 | |
| SCHEMBL15939366 | 0.86 | CASP3 (0.64) | CASP3CASP1CASP9CASP4CASP5 | |
| SCHEMBL4461379 | 0.84 | CASP3 (0.64) | CASP3CASP1CASP9CASP4CASP5 | |
| SCHEMBL29449496 | 0.83 | REN (0.52) | CASP3CASP1CASP9CASP4CASP5 | |
| SCHEMBL28714127 | 0.83 | REN (0.52) | CASP3CASP1CASP9CASP4CASP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10799552-B2 | Methods for treating diabetic neurotherapy | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2020-10-13 | — | — | US | disclosed |
| EP-2560629-B1 | METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2020-06-03 | — | — | EP | disclosed |
| US-10639345-B2 | Compositions for preserving photoreceptor cells, retinal pigment epithelial cells, or visual function | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2020-05-05 | — | — | US | disclosed |
| US-10617735-B2 | Methods and compositions for preserving retinal ganglion cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190216881-A1 | METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2019-07-18 | — | — | US | disclosed |
| US-20190117724-A1 | METHODS FOR TREATING SPINAL CORD INJURY | CHILDREN'S MEDICAL CENTER CORPORATION | 2019-04-25 | — | — | US | disclosed |
| US-20190099467-A1 | METHODS AND COMPOSITIONS FOR PRESERVING RETINAL GANGLION CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2019-04-04 | — | — | US | disclosed |
| US-10149884-B2 | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2018-12-11 | — | — | US | disclosed |
| US-10022419-B2 | Methods for treating spinal cord injury | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2018-07-17 | — | — | US | disclosed |
| US-9993517-B2 | Methods and compositions for preserving retinal ganglion cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2018-06-12 | — | — | US | disclosed |
| US-20110159004-A1 | Methods and Compositions for Preserving the Viability of Photoreceptor Cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2011-06-30 | — | — | US | disclosed |
| US-7811832-B2 | Methods for preserving the viability of photoreceptor cells by anti-FAS-ligand/anti-FAS-receptor antibodies | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100074882-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE VIABILITY OF PHOTORECEPTOR CELLS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2010-03-25 | — | — | US | disclosed |
| US-7592330-B2 | Methods and compositions for preserving the viability of photoreceptor cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080019909-A1 | Modulation of Programmed Necrosis | DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2008-01-24 | — | — | US | disclosed |
| US-20070287756-A1 | Methods and Compositions for Preserving the Viability of Photoreceptor Cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2007-12-13 | — | — | US | disclosed |
| WO-2007019427-A2 | METHODS AND COMPOSITIONS FOR PRESERVING THE VIABILITY OF PHOTORECEPTOR CELLS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032427-A1 | Methods and compositions for preserving the viability of photoreceptor cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2007-02-08 | — | — | US | disclosed |
| US-20050129684-A1 | Methods and compositions for preserving the viability of photoreceptor cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2005-06-16 | — | — | US | disclosed |
| WO-2003061519-A2 | METHODS AND COMPOSITIONS FOR PRESERVING THE VIABILITY OF PHOTORECEPTOR CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190099467-A1 | METHODS AND COMPOSITIONS FOR PRESERVING RETINAL GANGLION CELLS | GAP43, PDE6C, NGF | CASP3 10/4885CASP1 85/4885CASP9 31/4885 |
| US-10022419-B2 | Methods for treating spinal cord injury | NGF, GAP43, BDNF | CASP3 24/4885CASP1 65/4885CASP9 111/4885 |
| US-20190216881-A1 | METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS | ALDH1A2, PDE6B, PDE6C | CASP3 18/4885CASP1 140/4885CASP9 41/4885 |
| US-10149884-B2 | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells | ALDH1A2, PDE6B, PDE6C | CASP3 18/4885CASP1 140/4885CASP9 41/4885 |
| US-20190117724-A1 | METHODS FOR TREATING SPINAL CORD INJURY | NGF, GAP43, BDNF | CASP3 24/4885CASP1 65/4885CASP9 111/4885 |
| US-10799552-B2 | Methods for treating diabetic neurotherapy | NGF, NTRK2, BDNF | CASP3 22/4885CASP1 46/4885CASP9 206/4885 |
| US-10617735-B2 | Methods and compositions for preserving retinal ganglion cells | GAP43, PDE6C, NGF | CASP3 10/4885CASP1 85/4885CASP9 31/4885 |
| US-10639345-B2 | Compositions for preserving photoreceptor cells, retinal pigment epithelial cells, or visual function | ALDH1A2, PDE6B, PDE6A | CASP3 33/4885CASP1 205/4885CASP9 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.